Radiation, chemotherapy, and immunotherapy for advanced rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of radiation therapy, a chemotherapy drug called NALIRIFOX, and an immunotherapy drug called adebrelimab for rectal cancer that has grown into nearby tissue or lymph nodes. The goal is to see if this combination helps shrink the tumor before surgery and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Diagnosed with locally advanced rectal adenocarcinoma (cancer that has grown beyond the rectal wall or into lymph nodes, but not spread to distant organs)
- Good overall health and ability to handle treatment (ECOG score 0–1, meaning you can do light activities or are mostly bedridden only part of the day)
- Normal blood counts, liver function, and kidney function based on recent lab tests
- Expected to survive at least 2 years
- No prior radiation therapy to the pelvis or abdomen
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a shorter radiation course combined with two chemotherapy drugs and an immunotherapy drug for people with locally advanced rectal cancer that is microsatellite stable. The goal is to shrink the tumor before surgery, which may improve outcomes with fewer side effects.
This trial compares a new treatment approach—short-course radiation followed by an immunotherapy drug (PD-1 inhibitor) and chemotherapy (FOLFOX)—to the standard long-course chemoradiation for people with a specific type of advanced rectal cancer that is pMMR/MSS. The goal is to see if the shorter treatment works as well or better.
This trial tests a combination of a PD-L1 inhibitor (adebrelimab), short-course radiation, and chemotherapy given before surgery for locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This study tests a combination of radiation therapy, chemotherapy drugs (capecitabine and oxaliplatin), and two types of immunotherapy (a PD-1 blocker and IL-2) for locally advanced rectal cancer. The goal is to see if this combination helps shrink tumors and improve outcomes before surgery.
This trial combines a special type of radiation (MRI-guided adaptive radiotherapy) with an immunotherapy drug (PD-1 antibody) and chemotherapy (CAPOX) for locally advanced rectal cancer. The goal is to see if this combination can improve treatment outcomes.
This trial tests a new treatment sequence for locally advanced rectal cancer: a short course of radiation followed by a combination of immunotherapy (cadonilimab) and chemotherapy (mFOLFOX6) before surgery. The goal is to shrink the tumor more effectively and potentially improve outcomes.
Hear when a new Rectal Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.